Actively Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Led by Janssen Research & Development, LLC · Updated on 2026-05-08
400
Participants Needed
43
Research Sites
294 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.
CONDITIONS
Official Title
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Documented diagnosis of multiple myeloma according to international myeloma working group criteria
- Measurable disease at screening as assessed by central laboratory
- Received at least 3 prior lines of therapy including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody
- Documented evidence of progressive disease or failure to achieve a partial response or better to last therapy
- Discontinued any other anticancer treatment or investigational agent
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 at screening and before treatment start
You will not qualify if you...
- Active hepatitis of infectious origin
- Known active or prior central nervous system involvement or meningeal involvement of multiple myeloma
- Allergies, hypersensitivity, or intolerance to JNJ-79635322 or Teclistamab excipients
- Major surgery within 2 weeks before first dose or not fully recovered from surgery or surgery planned during study participation
- Received or plans to receive any live, attenuated vaccine within 4 weeks before first dose, during, or within 90 days after last dose of study treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 43 locations
1
USC Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
Actively Recruiting
2
University of Connecticut Health Center
Farmington, Connecticut, United States, 06030
Actively Recruiting
3
Yale Cancer Center
New Haven, Connecticut, United States, 06510
Actively Recruiting
4
Florida Cancer Specialists & Research Institute
Fort Myers, Florida, United States, 33901
Actively Recruiting
5
Moffit Cancer center
Tampa, Florida, United States, 33612
Actively Recruiting
6
Emory University
Atlanta, Georgia, United States, 30322
Actively Recruiting
7
University of Iowa Hospital and Clinics
Iowa City, Iowa, United States, 52242
Actively Recruiting
8
Mission Cancer Blood
Waukee, Iowa, United States, 50263
Actively Recruiting
9
Norton Cancer Institute
Louisville, Kentucky, United States, 40207
Actively Recruiting
10
Mount Sinai Brooklyn
Brooklyn, New York, United States, 11234
Actively Recruiting
11
Mount Sinai Chelsea
New York, New York, United States, 10011
Actively Recruiting
12
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
Actively Recruiting
13
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
14
Durham VAMC
Durham, North Carolina, United States, 27705
Actively Recruiting
15
Oregon Health And Science University
Portland, Oregon, United States, 97239
Actively Recruiting
16
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States, 19107
Actively Recruiting
17
Box Hill Hospital
Box Hill, Australia, 3128
Actively Recruiting
18
Mater Misericordiae Ltd
Brisbane, Australia, 4101
Actively Recruiting
19
Monash Medical Centre
Clayton, Australia, 3168
Actively Recruiting
20
St Vincents Hospital Melbourne
Fitzroy, Australia, 3065
Actively Recruiting
21
The Alfred Hospital
Melbourne, Australia, 3004
Actively Recruiting
22
Fiona Stanley Hospital
Murdoch, Australia, 6150
Actively Recruiting
23
Gold Coast University Hospital
Southport, Australia, 4215
Actively Recruiting
24
Hospital De Clinicas De Porto Alegre
Porto Alegre, Brazil, 90035 903
Suspended
25
Arthur J E Child Comprehensive Cancer Centre
Calgary, Alberta, Canada, T2N 4N1
Actively Recruiting
26
Soroka Medical Center
Beersheba, Israel, 8457108
Actively Recruiting
27
Bnai Zion Medical Center
Haifa, Israel, 31048
Actively Recruiting
28
Rambam Medical Center
Haifa, Israel, 3109601
Actively Recruiting
29
Carmel Medical Center
Haifa, Israel, 34362
Actively Recruiting
30
Shaare Zedek MC
Jerusalem, Israel, 9103102
Actively Recruiting
31
Sheba Medical Center
Ramat Gan, Israel, 52621
Actively Recruiting
32
Baruch Padeh MC
Ramat Poriya, Israel, 1520800
Actively Recruiting
33
Assuta MC
Tel Aviv, Israel, 69710
Actively Recruiting
34
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
Bunkyō City, Japan, 113 8677
Actively Recruiting
35
Chiba Cancer Center
Chiba, Japan, 260 0801
Actively Recruiting
36
Shonan Kamakura General Hospital
Kamakura-shi, Japan, 247-8533
Actively Recruiting
37
Kameda Medical Center
Kamogawa, Japan, 296-8602
Actively Recruiting
38
Yamanashi Prefectural Central Hospital
Kofu, Japan, 400-0027
Actively Recruiting
39
The Jikei University Hospital
Minato, Japan, 105-8471
Actively Recruiting
40
Japanese Red Cross Medical Center
Shibuya City, Japan, 150-8935
Actively Recruiting
41
Kanagawa Cancer Center
Yokohama, Japan, 241 8515
Actively Recruiting
42
Kent and Canterbury Hospital
Canterbury, United Kingdom, CT1 3NG
Actively Recruiting
43
Ninewells Hospital & Medical School
Dundee, United Kingdom, DD1 9SY
Actively Recruiting
Research Team
S
Study Contact
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here